A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy
RecruitingOBSERVATIONAL
Enrollment
60
Participants
Timeline
Start Date
July 10, 2025
Primary Completion Date
November 12, 2030
Study Completion Date
November 12, 2030
Conditions
Biliary Tract Cancer
Interventions
OTHER
No Intervention
This is a non-interventional study.
Trial Locations (1)
Unknown
RECRUITING
#Eisai Trial Site 1, Tokyo
All Listed Sponsors
lead
Eisai Co., Ltd.
INDUSTRY
NCT06793709 - A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy | Biotech Hunter | Biotech Hunter